Hutter Lab


The Hutter Laboratory was established in October 2021 at The Queen’s Medical Center. The lab is headed by Randolph Hutter, MD and located within the University of Hawaii Tower on the campus of The Queen’s Medical Center.

The Science

Dr. Hutter is a cardiologist and physician-scientist with dual NIH-funded training in clinical practice and clinical research. He is board certified in Internal Medicine and Cardiovascular Diseases. He is the Principal Investigator of a prospective clinical trial entitled “Role of Podocan and Wnt-Pathway Regulatory Molecules in Coronary Artery Disease” (NCT02807714) that ran between 2016 and 2021, and was based on his ground breaking laboratory work on podocan physiology in cardiovascular disease. He continues to have a strong interest in developing this work further, both on the in vitro mechanistic level as well as translating it into clinical care. Dr. Hutter is synergistically collaborating with Dr. Johnson on this project and his experience in human subject protection, animal subject protection, in vitro analyses and biostatistical analyses of data derived from prospective clinical studies provide a unique opportunity for his patients in Hawaii and beyond.


Hutter Lab Members

Randolph Hutter, MD

Principal Investigator
Fax: 1 (808) 691-7939


Brandon E. Johnson, PhD

Tel: 1 (808) 691-4261
Fax: 1 (808) 691-7939

Selected Publications

A new approach to treat advanced atherosclerosis with in vivo caspase inhibition: Evidence from an animal model

Hutter R., Speidl W.S., Valdiviezo C., Sauter B., Fuster V., Badimon J.J.
Cardiovasc. Transl. Res. (2022). In revision.

Alternatively spliced tissue factor promotes plaque angiogenesis through the activation of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor signaling

Giannarelli C., Alique M., Rodriguez D.T., Yang D.K., Jeong D., Calcagno C., Hutter R., Milon A., Kovacic J.C., Weber T., Faries P.L., Soff G.A., Fayad Z.A., Hajjar R.J., Fuster V., Badimon J.J.Circulation 130:1274 (2014)

An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents

Katsaros K.M., Kastl S.P., Krychtiuk K.A., Hutter R., Zorn G., Maurer G., Huber K., Wojta J., Christ G., Speidl W.S.
Eurointervention 10:224 (2014)

The novel small leucine-rich repeat protein podocan is a negative regulator of migration and proliferation of smooth muscle cells, modulates neointima fomration and is expressed in human atheroma

Hutter R., Huang L., Speidl W.S., Giannarelli C., Trubin P., Bauriedel G., Klotman M., Fuster V., Badimon J.J., Klotman P.
Circulation 128:2351 (2013)

Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1alpha activation: a novel aspect of angiogenesis in atherosclerosis

Hutter R., Speidl W.S., Valdiviezo C., Sauter B., Corti R., Fuster V., Badimon J.J.
J. Cardiovasc. Transl. Res 6:558 (2013)

Accelerated reendothelialization, increased neovascularization and erythrocyte extravasion after arterial injury in BAMI-/- mice

Guillot N., Kollins D., Badimon J.J., Schondorff D., Hutter R.
PLOS One 8:e58550 (2013)